West Reports Fourth-Quarter and Full-Year 2025 Results

Core Insights - West Pharmaceutical Services reported strong financial results for Q4 and full year 2025, driven by double-digit organic revenue growth in High-Value Product (HVP) Components [1][2] - The company expects continued positive momentum into 2026, emphasizing operational excellence and sustainable growth [1] Financial Performance - Q4 2025 net sales reached $805.0 million, a 7.5% increase year-over-year, with organic growth of 3.3% [1][2] - Full-year 2025 net sales totaled $3.074 billion, up 6.3% from the previous year, with organic growth of 4.3% [1][2] - Adjusted diluted EPS for Q4 2025 was $2.04, a 12.1% increase, while full-year adjusted diluted EPS was $7.29, an 8.0% increase [1][2] Segment Performance - Proprietary Products Segment saw Q4 net sales of $661.8 million, growing 7.8% overall and 3.6% organically [1][2] - High-Value Product Components within the Proprietary Products Segment reported net sales of $389.8 million, a 20.3% increase, with organic growth of 15.1% [1][2] - Contract-Manufactured Products Segment net sales increased by 6.2% to $143.2 million, with organic growth of 1.9% [1][2] Shareholder Returns - In 2025, the company repurchased 552,593 shares for $134.0 million at an average price of $242.55 [1][2] - Operating cash flow for 2025 was $754.8 million, a 15.5% increase, with free cash flow rising 69.6% to $468.9 million [1][2] 2026 Financial Guidance - For full-year 2026, net sales are projected to be between $3.215 billion and $3.275 billion, with organic growth expected to be approximately 5% to 7% [1][2] - Reported growth for 2026 is anticipated to be between 4.6% and 6.5% [1][2]